logo-loader
RNS
viewPhysiomics PLC

Physiomics PLC - Contract award

RNS Number : 7178X
Physiomics PLC
23 December 2019
 

23 December 2019

Physiomics plc

("Physiomics") or (the "Company")

 

 

Contract award

 

Physiomics signs further project agreement with CellCentric

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a further contract by existing UK based biotech client, CellCentric.  The value of the contract is not disclosed but is expected to complete in the first half of 2020.

 

The project will involve pharmacokinetic and pharmacodynamic modelling and build on the work completed over the course of 2019 in support of the clinical development of CellCentric's lead asset CCS1477.  This is a first in class small molecule inhibitor of p300/CBP, currently in Phase 1/2 trials for the treatment of late stage, drug-resistant prostate cancer as well as haematological malignancies. 

 

A summary of some of the work that the Company has previously completed with CellCentric is available as a case study on the Physiomics website and can be accessed using the following hyperlink: https://www.physiomics.co.uk/wp-content/uploads/2019/03/CC-case-study.pdf.

 

Dr Jim Millen, CEO said:

"We are looking forward to continuing to work with CellCentric, one of the UK's most exciting young biotech companies."

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 20 3764 2341

 

 

Notes to Editor

 

About Physiomics

 

Physiomics® is an oncology consultancy which uses mathematical PKPD models as well as its proprietary Virtual Tumour™ technology to predict the effects of cancer drugs and treatments and improve the success rate of drug discovery and development projects. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

 

For more information please visit:

www.physiomics-plc.com

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAPGGCUPUPBGQU

Quick facts: Physiomics PLC

Price: 2.4

Market: AIM
Market Cap: £1.73 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE